Abstract
Objectives:Media reports suggest increased cardiovascular mortality in former National Football League (NFL) players. We previously demonstrated that current heavier players already have cardiometabolic syndrome markers: blood pressure (BP) ≥130/85 mm Hg, fasting glucose ≥100 mg/dL, triglycerides ≥150 mg/dL, waist circumference ≥100 cm, and high-density lipoprotein (HDL) ≤40 mg/dL.Methods:A prospective study including 69 of 91active players (76%) from one NFL team was performed. We evaluated the presence of an elevated alanine aminotransferase (ALT) in the players. We also analyzed the association of an increased ALT with cardiometabolic syndrome markers, waist-to-height ratio, and triglyceride-to-HDL ratio in current NFL players.Results:ALT ≥30 IU/L was significantly correlated with mean body mass index (BMI), BMI ≥30 kg/m2, BP ≥130/85 mm Hg, waist circumference ≥100 cm, and triglycerides-to-HDL ratio >3.5. An elevated ALT was significantly more common in linemen.Conclusions:An elevated ALT was significantly associated with visceral obesity, hypertension, cardiometabolic syndrome markers, and insulin resistance in current NFL players.
This content is limited to qualifying members.
If you have an existing account please login now to access this article or view purchase options.
Create a free account, then purchase this article to download or access it online for 24 hours.
Create a free account, then purchase a subscription to get complete access to all articles for a full year.
References
References1. Hargrove T. Supersized in the NFL: many ex-players dying young. Scripps Howard News Service Online, 2006.HargroveTSupersized in the NFL: many ex-players dying young.Scripps Howard News Service Online2006&NA;&NA;2. National Institute for Occupational Safety and Health. NFL Mortality Study. Available at: http://www.cdc.gov/niosh/pdfs/nflfactsheet.pdf. Accessed September 1, 2008.3. Miller MA, Croft LB, Belanger AR, et al. Prevalence of metabolic syndrome in retired National Football League players. Am J Cardiol 2008;101:1281–1284.MillerMA]]CroftLB]]BelangerAR&etal;Prevalence of metabolic syndrome in retired National Football League players.Am J Cardiol20081011281-12844. Selden MA, Helzberg JH, Waeckerle JF, et al. Cardiometabolic abnormalities in current National Football League players. Am J Cardiol 2009;103:969–971.SeldenMA]]HelzbergJH]]WaeckerleJF&etal;Cardiometabolic abnormalities in current National Football League players.Am J Cardiol2009103969-9715. Machado M, Cortez-Pinto H. Non-alcoholic steatohepatitis and metabolic syndrome. Curr Opin Clin Nutr Metab Care 2006;9:637–642.MachadoM]]Cortez-PintoHNon-alcoholic steatohepatitis and metabolic syndrome.Curr Opin Clin Nutr Metab Care20069637-6426. Dixon JB, Bhathal PS, O’Brien PE. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 2001;121:91–100.DixonJB]]BhathalPS]]O’BrienPENonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese.Gastroenterology200112191-1007. Targher G. Non-alcoholic fatty liver disease, the metabolic syndrome and the risk of cardiovascular disease: the plot thickens. Diabet Med 2007;24:1–6.TargherGNon-alcoholic fatty liver disease, the metabolic syndrome and the risk of cardiovascular disease: the plot thickens.Diabet Med2007241-68. Ioannou GN, Weiss NS, Boyko EJ, et al. Elevated serum alanine aminotransferase activity and calculated risk of coronary heart disease in the United States. Hepatology 2006;43:1145–1151.IoannouGN]]WeissNS]]BoykoEJ&etal;Elevated serum alanine aminotransferase activity and calculated risk of coronary heart disease in the United States.Hepatology2006431145-11519. Schindhelm RK, Dekker JM, Nijpels G, et al. Alanine aminotransferase predicts coronary heart disease events: a 10-year follow-up of the Hoorn Study. Atherosclerosis 2007;191:391–396.SchindhelmRK]]DekkerJM]]NijpelsG&etal;Alanine aminotransferase predicts coronary heart disease events: a 10-year follow-up of the Hoorn Study.Atherosclerosis2007191391-39610. Ioannou GN. Implications of elevated serum alanine aminotransferase levels: think outside of the liver. Gastroenterology 2008;135:1851–1854.IoannouGNImplications of elevated serum alanine aminotransferase levels: think outside of the liver.Gastroenterology20081351851-185411. Goessling W, Massaro JM, Vasan RS, et al. Aminotransferase levels and 20-year risk of metabolic syndrome, diabetes, and cardiovascular disease. Gastroenterology 2008;135:1935–1944.GoesslingW]]MassaroJM]]VasanRS&etal;Aminotransferase levels and 20-year risk of metabolic syndrome, diabetes, and cardiovascular disease.Gastroenterology20081351935-194412. Vozarova B, Stefan N, Lindsay RS, et al. High alanine aminotransferase is associated with decreased hepatic insulin sensitivity and predicts the development of type 2 diabetes. Diabetes 2002;51:1889–1895.VozarovaB]]StefanN]]LindsayRS&etal;High alanine aminotransferase is associated with decreased hepatic insulin sensitivity and predicts the development of type 2 diabetes.Diabetes2002511889-189513. Prati D, Taioli E, Zanella A, et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 2002;137:1–10.PratiD]]TaioliE]]ZanellaA&etal;Updated definitions of healthy ranges for serum alanine aminotransferase levels.Ann Intern Med20021371-1014. Van der Poorten D, Kenny DT, Butler T, et al. Liver disease in adolescents: a cohort study of high-risk individuals. Hepatology 2007;46:1750–1758.Van der PoortenD]]KennyDT]]ButlerT&etal;Liver disease in adolescents: a cohort study of high-risk individuals.Hepatology2007461750-175815. Gelber RP, Gaziano JM, Orav EJ, et al. Measures of obesity and cardiovascular risk among men and women. J Am Coll Cardiol 2008;52:605–615.GelberRP]]GazianoJM]]OravEJ&etal;Measures of obesity and cardiovascular risk among men and women.J Am Coll Cardiol200852605-61516. Kannel WB, Vasan RS, Keyes MJ, et al. Usefulness of the triglyceride-high-density lipoprotein versus the cholesterol-high-density lipoprotein ratio for predicting insulin resistance and cardiometabolic risk (from the Framingham Offspring Cohort). Am J Cardiol 2008;101:497–501.KannelWB]]VasanRS]]KeyesMJ&etal;Usefulness of the triglyceride-high-density lipoprotein versus the cholesterol-high-density lipoprotein ratio for predicting insulin resistance and cardiometabolic risk (from the Framingham Offspring Cohort).Am J Cardiol2008101497-50117. Cordero A, Laclaustra M, León M, et al; MESYAS Registry Investigators. Comparison of serum lipid values in subjects with and without the metabolic syndrome. Am J Cardiol 2008;102:424–428.CorderoA]]LaclaustraM]]LeónM&etal;MESYAS Registry InvestigatorsComparison of serum lipid values in subjects with and without the metabolic syndrome.Am J Cardiol2008102424-42818. McLaughlin T, Abbasi F, Cheal K, et al. Use of metabolic markers to identify overweight individuals who are insulin resistant. Ann Intern Med 2003;139:802–809.McLaughlinT]]AbbasiF]]ChealK&etal;Use of metabolic markers to identify overweight individuals who are insulin resistant.Ann Intern Med2003139802-80919. da Luz PL, Favarato D, Faria-Neto JR Jr, et al. High ratio of triglycerides to HDL-cholesterol ratio predicts extensive coronary disease. Clinics (Sao Paulo) 2008;63:427–432.da LuzPL]]FavaratoD]]Faria-NetoJRJr&etal;High ratio of triglycerides to HDL-cholesterol ratio predicts extensive coronary disease.Clinics (Sao Paulo)200863427-43220. Ostfeld R, Mookherjee D, Spinelli M, et al. A triglyceride/high-density lipoprotein ratio > or = 3.5 is associated with an increased burden of coronary artery disease on cardiac catherization. J Cardiometab Syndr 2006;1:13–15.OstfeldR]]MookherjeeD]]SpinelliM&etal;A triglyceride/high-density lipoprotein ratio > or = 3.5 is associated with an increased burden of coronary artery disease on cardiac catherization.J Cardiometab Syndr2006113-1521. Harp JB, Hecht L. Obesity in the National Football League. JAMA 2005;293:1061–1062.HarpJB]]HechtLObesity in the National Football League.JAMA20052931061-1062
